GV and Novartis Venture Fund joined 6 Dimensions Capital in a round that brought the oncology drug developer's overall funding to $160m.

The Regeneron, Alphabet and GlaxoSmithKline-backed hearing loss therapy developer has filed to raise up to $75m in its initial public offering.

Northpond and Deerfield have co-led a $75m series C round for Encodia, seemingly the first publicly disclosed funding for the WashU spinout.

Nan Fung Life Sciences’ Pivotal BioVenture Partners co-led a $35m extension to the cancer therapy developer’s series A round.

Northpond and Deerfield have co-led a $75m series C round for protein analysis system developer Encodia that included GV and Nan Fung Life Sciences.

Landos has filed to go public after a phase 2 trial of its Virginia Tech-invented IBD treatment produced favourable results this month.

The firm's LAV Fund VI and LAV Fund VI Opportunities funds have been supplied by $100m from Los Angeles County Employees Retirement Association.

Baupost Group has led another round for Wren Therapeutics, a spinout of Cambridge and Lund universities.

Heritage Group has added $317m having previously raised $220m for its second fund four years ago.

The virtual care app developer has added $8m of additional capital to its series B round backed by Northwell Ventures and UH Ventures.